Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Experts Take Stock of Frontline Immunotherapy Combos in NSCLC

Christin L. Melton, ELS
Published: Wednesday, Jan 08, 2020
Suresh S. Ramalingam, MD, FASCO, the Roberto C. Goizueta Chair for Cancer Research, professor, Department of Hematology and Medical Oncology, and deputy director of the Winship Cancer Institute of Emory University

Suresh S. Ramalingam, MD, FASCO

Immune checkpoint inhibitors (ICIs) have advanced rapidly in the management of non–small cell lung cancer (NSCLC), graduating from a salvage option to a frontline regimen. Despite the agents’ ability to produce durable responses and prolong overall survival (OS) in some patients with cancer, primary and acquired resistance remain significant obstacles.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication